Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
REGULATORY
MHLW Pitches Dispensing Fee Cuts for Hospitals, Pharmacies with Low Price Settlement Rates
The Ministry of Health, Labor and Welfare (MHLW) made a proposal to a key advisory council on December 25 to shed basic dispensing fees for major hospital groups and pharmacy chains with low delivery price settlement rates. The proposal, floated…
To read the full story
Related Article
- Discarded Plan to Institutionalize Key Premium Still Faces Backlash; Rough Sailing Expected before Next Reform
December 27, 2013
- Chuikyo Reps Slam Inter-Ministerial Deal to Scrap Insurance Coverage for Gargles
December 27, 2013
- Chuikyo Approves 60% Upper Limit for Evaluating Generic Drug Use at DPC Hospitals
December 27, 2013
- Trial of Cost-Effective Assessment Should Be Postponed Until FY2016 at Earliest: Expert Subcommittee
December 27, 2013
- Gist of FY2014 NHI Price Revision
December 26, 2013
- Chuikyo Approves Outline for NHI Price Reform Including New Rule for Long-Listed Drugs; Trial of Premium for New Drug Development to Continue
December 26, 2013
REGULATORY
- MHLW Seeks Comments on Rx-to-OTC Switch of Tadalafil, 2 Other APIs
November 27, 2024
- JPMA Calls for Legal Framework to Facilitate Use of Pseudonymized Data
November 27, 2024
- Japan Likely to Extend “Catch-Up” HPV Vaccination Program
November 26, 2024
- As 2025 Budgeting Nears, “No” to Off-Year Revisions Arises from LDP Too
November 26, 2024
- Japan Gets Down to the Business of Solving Drug Loss, New Scheme Begins with 78 Meds
November 26, 2024
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…